ACC 2016 BEST OF THE REST: Surgery Trials, More CoreValve Data, Leadless Pacemakers, Drug-Filled Stents, And More
This article was originally published in Clinica
Executive Summary
Almost 19,000 people were in Chicago April 2-4 for the 2016 American College of Cardiology's Annual Scientific Sessions, which featured over 2,400 presentations, including 24 late-breaking trials and 10 other clinical research presentations. Edwards’ transcatheter valves grabbed most of the headlines, but here are some of the other highlights from medical device trial results presented at the meeting
You may also be interested in...
TCT 2018: Medtronic's CoreValve Proves Durable Out To Five Years
The five-year results from the US pivotal high-risk trial of Medtronic's CoreValve transcatheter aortic valve, the longest-term follow-up data from a randomized trial of CoreValve, show the valve remains durable with low rates of severe hemodynamic structural valve deterioration compared to surgical valves.
ACC 2017: SURTAVI Supports Intermediate-Risk Intervention For Medtronic's CoreValve
In an interview with Medtech Insight, the lead investigator of SURTAVI, an ongoing trial of Medtronic's CoreValve in intermediate risk patents, says transcatheter aortic valve is continuously improving and will probably soon be indicated for even low-risk patients, but that surgical valve replacement will have an important role to play for the foreseeable future.
US FDA Approves First Intermediate-Risk Indication For TAVR
The expanded indication for Edwards' Sapien XT and Sapien 3 arrives about when the company had predicted.